No CrossRef data available.
Article contents
Re-evaluating benzodiazepines for anxiety disorders – déjà-vu all over again?
Published online by Cambridge University Press: 09 January 2023
Summary
Benzodiazepines have attracted controversy from shortly after their introduction. They have been subject to periodic calls for their use to be re-evaluated on the basis that their risks have been overstated and their benefits underappreciated. Claims made in recent editorials from the International Task Force on Benzodiazepines in support of their wider use are critiqued in this issue. I examine here whether there is a case to change the conclusions of previous reconsiderations of the question.
- Type
- Commentary
- Information
- Copyright
- Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists
Footnotes
Commentary on… The devil is in the detail. See this issue.
eLetters
No eLetters have been published for this article.